Sunshine Biopharma Inc (SBFM)

[Really People]

Scott Pagan: Director of UGA Center for Drug Development, Professor and Interim Associate Head, Department of Pharmaceutical and Biomedical Sciences; expert in small molecule anti-viral and vaccine development for coronaviruses, nairoviruses and arteriviruses.

David Crich The Crich Lab UGA
https://rx.uga.edu/faculty-member/david-crich-dessc/

As part of its land grant tripartite mission, the University of Georgia is committed to creating and applying new knowledge for the public good. UGA’s Center for Drug Discovery as well as the Colleges of Pharmacy are excited to be a part of this ground-breaking research related to discovery of new treatment options for COVID-19. Profs. Scott Pegan, and David Crich will be working with Sunshine Biopharma to spearhead the study of novel therapeutics for the prevention and spread of COVID-19. This interdisciplinary effort involves state of the art approaches in chemical synthesis and drug screening. This continues University of Georgia’s long-standing tradition in translating scientific breakthroughs to address real world health concerns.

https://sunshinebiopharma.com/assets/press/SBFM_Press%20Release_October6_%202020_Identifies_a_Lead%20Compound_V2-sp%20(1)_Redline2_Clean.pdf

“Should these mice studies prove successful, we plan to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited to have initiated this
pivotal study on transgenic mice with the University of Georgia. The implications of a COVID-19 treatment becoming available are vast. This is particularly the case in view of the fact that some of the variants emerging around the world are more virulent and may escape neutralization by the current vaccines,” he added.